Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemotherapy in ECOG PS 2 NSCLC
NCT05965102Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Objective Response Rate. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05965102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965102.